6-氨基咪唑并[1,2-A]吡啶-2-羧酸 | 886363-86-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 6-氨基咪唑并[1,2-A]吡啶-2-羧酸
• 英文名称: 6-Aminoimidazo[1,2-a]pyridine-2-carboxylic acid
• CAS: 886363-86-6
• 化学式: C₈H₇N₃O₂
• mdl: MFCD07374364
• 分子量: 177.16
• InChiKey: DOZRRDMNSHDPHW-UHFFFAOYSA-N

物化性质

• 密度：
  1.59

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• DÉRIVÉS D'IMIDAZO[1,2-A]PYRIDINE-2-CARBOXAMIDES LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE
  申请人：Sanofi-Aventis

  公开号：EP2041133A1

  公开（公告）日：2009-04-01
• Composés de N-phényl-imidazo(1,2-a)pyridine-2-carboxamides, leur préparation et leur application en thérapeutique
  申请人：SANOFI

  公开号：EP2225245B1

  公开（公告）日：2011-10-19
• Novel cc-1065 Analogs and Their Conjugates
  申请人：Beusker Patrick Henry

  公开号：US20110207767A1

  公开（公告）日：2011-08-25

  This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.
• PROCESS FOR MAKING DUOCARMYCIN PRODRUGS
  申请人：Synthon Biopharmaceuticals B.V.

  公开号：US20170145006A1

  公开（公告）日：2017-05-25

  The present invention relates to a process comprising converting a compound of formula (I) into a compound of formula (II) by reaction with an organolithium reagent, which compound can be further converted into duocarmycin analogues consisting of a DNA-alkylating and a DNA-binding part, and still further into corresponding antibody-drug conjugates.
• SUBSTITUTED OXOPYRIDINE DERIVATIVES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20180250280A1

  公开（公告）日：2018-09-06

  The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.